CU2.F Cerus Corporation

Healthcare Health Care Equipment & Supplies Frankfurt Exchange
1.89 EUR
Close of Nov 12, 2026
1.27 2.96
Market cap
EUR 382M
P/E
-
P/B
5.48x
ROE
-9.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CU2.F undervalued?

Graham number

The Graham number of Cerus Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cerus Corporation fundamental analysis

No fundamental analysis for Cerus Corporation yet.

Cerus Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cerus Corporation

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is …

Full company profile